(R/S)-Alicaforsen

SKU HY-145728B-1 mg Category Tags , ,

$200$820

Products Details

Product Description

– (R/S)-Alicaforsen is the racemate of Alicaforsen composed of R and S configurations. Alicaforsen is a 20-base antisense oligonucleotide inhibiting ICAM-1 production, which is an important adhesion molecule involved in leukocyte migration and trafficking to the site of inflammation.

Web ID

– HY-145728B

Storage Temperature

– -20°C (Powder, sealed storage, away from moisture)

Shipping

– Blue Ice

Applications

– COVID-19-immunoregulation

Molecular Formula

– N/A

References

– [1]Henry SP, et al. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in CD-1 mice. Antisense Nucleic Acid Drug Dev. 1997;7(5):473-481.|[2]Henry SP, et al. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys. Toxicology. 1997;120(2):145-155. |[3]Henry SP, et al. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in CD-1 mice. Antisense Nucleic Acid Drug Dev. 1997;7(5):473-481.

Molecular Weight

– 6368.00

Compound Purity

– 97.08

SMILES

– [(R/S)-Alicaforsen]

Clinical Information

– No Development Reported

Research Area

– Inflammation/Immunology

Solubility

– H2O : 100 mg/mL (ultrasonic)

Target

– Integrin

Pathway

– Cytoskeleton

Product type

– Oligonucleotides

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

=

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.

=